| Drug Name |
Ranibizumab |
| Drug ID |
BADD_D01912 |
| Description |
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis® and was recently approved under the name Susvimo as an intraocular implantation.[L38983] It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. |
| Indications and Usage |
For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
|
| Marketing Status |
approved |
| ATC Code |
S01LA04 |
| DrugBank ID |
DB01270
|
| KEGG ID |
D05697
|
| MeSH ID |
D000069579
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D04EYG
|
| NDC Product Code |
71082-110; 50242-080; 50242-183; 82775-100; 50242-078; 68225-123; 50242-082; 71082-111 |
| UNII |
ZL1R02VT79
|
| Synonyms |
Ranibizumab | RhuFab V2 | V2, RhuFab | Lucentis |
